GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES

Brief description of study

The purpose of the study is to evaluate the efficacy of a CDK, PI3K or NTRK/ROS1 inhibitor in patients with progressive brain metastases harboring the alterations predicting sensitivity to each of these inhibitors. We want to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. Patient’s tumor samples will be tested for the presence of mutations predicting sensitivity to each inhibitor. Patients harboring these mutations and who meet eligibility will be enrolled.


Clinical Study Identifier: s20-00785
ClinicalTrials.gov Identifier: NCT03994796
Principal Investigator: Christine Cordova.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.